Hodgkin Lymphoma Clinical Trials

• Histologically documented primary central nervous system(CNS) lymphoma or secondary diffuse large B-cell lymphoma (DLBCL) isolated to CNS.

• Relapsed or refractory disease with at least 1 prior methotrexate-based therapy

• Participant must be able to understand and willing to sign a written informed consent document.

• Participant must have signed and dated written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.

• Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.

• Participant must be at least 18 years old on day of signing informed consent.

• PCNSL subjects should have evidence of measurable or evaluable enhancing disease on MRI

• Able to submit at least 10 but up to 20 unstained formalin-fixed, paraffin-embedded (FFPE) slides from the initial or most recent tissue diagnosis for correlative studies. Histologically confirmed tissue will be required from the time of relapse or at the time of initial surgery. If tissue is unavailable and/or diagnosis was made from cerebrospinal fluid or vitreal biopsy, approval from the overall principal investigator is needed.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3.

⁃ Life expectancy of \>3 months (in the opinion of the investigator)

⁃ Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1

⁃ Must be able to tolerate lumbar puncture and MRI/CT.

⁃ Demonstrate adequate organ function as defined below, all screening labs should be performed within 14 days of treatment initiation.

∙ Absolute neutrophil count (ANC) ≥ 1.0 x 109/L

‣ Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 7 days prior to initiation of protocol treatment

‣ Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR) \< 2 times the upper limit of normal

‣ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal

‣ Serum bilirubin ≤ 1.5 times the upper limit of normal

‣ Creatinine clearance \> 30 mL/min calculated by the Cockcroft-Gault formula using actual body weight

⁃ Women of child-bearing potential, must agree to use a highly effective method of contraception consistently and correctly as described below during study treatment and for 120 days after study discontinuation.

⁃ Male participants must agree to use at least one of the following methods of contraception starting with the first dose of study therapy through 120 days after the last dose of therapy:

⁃ Ability to swallow oral medications.